Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 700-708

  Velazquez, Francisco ^a   Venkatraman, Srikanth ^a   Blackman, Melissa ^a   Pinto, Patrick ^a   Bogen, Stephane ^a   Sannigrahi, Mousumi ^a   Chen, Kevin ^a   Pichardo, John ^a   Hart, Andrea ^a   Tong, Xiao ^a   Girijavallabhan, Viyyoor ^a   Njoroge, F George ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 [[[[1 [(2,4 DIOXO 3 AZABICYCLO[3.2.1]OCT 3 YL)METHYL] 2,2 DIMETHYLPROPYL]AMINO]CARBONYL]AMINO]HEXADECAHYDRO 12,17,17 TRIMETHYL ALPHA,1,14 TRIOXO N (2 PROPENYL) 2H,12H CYCLOPROPA[3,4]PYRROLO[1,2 E][1,5,8]OXADIAZACYCLOHEXADECINE 3 ACETAMIDE; BOCEPREVIR; MACROCYCLIC COMPOUND; NONSTRUCTURAL PROTEIN 3; OXYGEN; PEPTIDOMIMETIC AGENT; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; CYCLIZATION; DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C VIRUS; NONHUMAN; RING CLOSING METATHESIS; VIRUS REPLICATION; DRUG ANTAGONISM; DRUG DESIGN; EVALUATION; SYNTHESIS;

ANTIVIRAL AGENTS; DRUG DESIGN; MACROCYCLIC COMPOUNDS; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 61449240242     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801201u     Document Type: Article

References (36)

1. (a) Hepatitis C. Fact Sheet No. 164; World Health Organization (WHO): Geneva, Switzerland, Revised October 2000. WHO Web site: http://www.who.int/ mediacentre/factsheets/fs164/en/
2. (b) Wasley, A.; Alter, M. J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin.Liver Dis. 2000, 20, 1-16.
3. (c) Brown, R. S. Jr; Gaglio, P. J. Scope of worldwide hepatitis C problem. Liver Transplant. 2003, 9, S10-S13.
4. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41-52.
5. (a) McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M-H.; Cort, S.; Albrecht, J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998, 339, 1485-1492.
6. (b) Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Goncales, F. L., Jr.; Haussinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-982.
7. Poynard, T.; Marcellin, P.; Lee, S. S.; Niederau, C.; Minuk, G. S.; Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem, S.; Trepo, C.; Albrecht, J. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352, 1426-1432.
8. Choo, Q. L.; Kuo, G.; Weiner, A. G.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359-362.
9. Lindenbach, B. D.; Rice, C. M. Unraveling hepatitis C virus replication from genome to function. Nature 2005, 436, 933-938.
10. Bartenschlager, R.; Ahlborn-Laake, L.; Mous, J.; Jacobsen, H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67, 3835-3844.
11. (a) Goudreau, N.; Llinàs-Brunet, M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin. Invest. Drugs 2005, 14, 1129-1144.
12. (b) Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discovery 2007, 6, 991-1000.
13. (c) Sheldon, J.; Barreiro, P.; Soriano, V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin. Invest. Drugs 2007, 16, 1171-1181.
14. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madision, Broske, L.; Cui, X.; Cheng, K-C.; Hsieh, T. Y.; Brisson, J-M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogonowich - Knipp, S.; Pavlovsky, A.; Prudence, B.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1R,5S)-N-[3-amino-1- (cyclobutylmethyl)-2-3-dioxopropyl]-3-[2(S) - [[[(1,1-dimethylethyl)-amino] carbonyl]amio]-3,3-dimethyl-1-oxobutyl] - 6,6-dimethyl-3-azabicyclo[3.1.0]hexan- 2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49, 6074-6086.
15. Schering-Plough Press Release Aug 4th, 2008: Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients; Schering-Plough: Kenilworth, NJ, 2008. Schering-Plough Web site: http://www.schering-plough.com/news/news- article.aspx?reqid=1182855.
16. (a) Yip, Y.; Victor, F.; Lamar, J.; Johnson, R.; Wang, Q. M.; Glass, J. I.; Yumibe, N.; Wakulchik, M.; Munroe, J.; Chen, S.-H. P4 and P1′ optimization of bicycloproline P2 bearing tetrapeptidyl α-keto - amides as HCV protease inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 5007-5011.
17. (b) Chen, S.-H.; Lamar, J.; Yip, Y.; Victor, F.; Johnson, R. B.; Wang, Q. M.; Glass, J. I.; Heinz, B.; Colacino, J.; Guo, D.; Tebbe, M.; Munroe, J. E. P1 and P1′ optimization of [3,4] - bicycloproline P2 incorporated tetrapeptidyl α-ketoamide based HCV protease inhibitors. Lett. Drug Des. Discovery 2005, 2, 118-123.
18. (c) Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally, bioavailable inhibitor of hepatitis C virus NS3 - 4A serine protease. Antimicrob. Agents Chemother. 2006, 50, 899-909.
19. (a) Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bos, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagace, L.; LaPlante, S. R.; Narjes, H.; Poupart, M-A.; Rancourt, J.; Sentjens, R. E.; George, T. S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinas-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426, 186-189.
20. (b) Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure - activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery ofBILN 2061. J. Med. Chem. 2004, 47, 1605-1608.
21. For recent examples, see the following: (a) Grieco, P.; Cai, M.; Liu, L.; Mayorov, A.; Chandler, K.; Trivedi, D.; Lin, G.; Campiglia, P.; Novellino, E.; Hruby, V. J. Design and microwave-assisted synthesis of novel macrocyclic peptides active at melanocortin receptors: discovery of potent and selective hMC5R receptor antagonists. J. Med. Chem. 2008, 51, 2701-2707.
22. (b) Marsault, E.; Hoveyda, H. R.; Peterson, M. L.; Saint-Louis, C.; Landry, A.; Vézina, M.; Ouellet, L.; Wang, Z.; Ramaseshan, M.; Beaubien, S.; Benakli, K.; Beauchemin, S.; Déziel, R.; Peeters, T.; Fraser, G. L. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J. Med. Chem. 2006, 49, 7190-7197.
23. For reviews, see the following: (c) Li, P.; Roller, P. P. Cyclization strategies in peptide derived drug design. Curr. Top. Med. Chem. 2002, 2, 325-341.
24. (d) Li, P.; Roller, P. P.; Xu, J. Current synthetic approaches to peptide and peptidomimetic cyclization. Curr. Org. Chem. 2002, 6, 411-440.
25. (a) Venkatraman, S.; Njoroge, F. G.; Girijavallabhan, V. M.; Madison, V.; Yao, N. H.; Prongay, A. J.; Butkiewicz, N.; Pichardo, J. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design. J. Med. Chem. 2005, 48, 5088-5091.
26. (b) Chen, K. X.; Njoroge, F. G.; Vibulbhan, B.; Prongay, A.; Pichardo, J.; Madison, V.; Buevich, A.; Chan, T.-M. Proline-based macrocyclic inhibitors of the hepatitis C virus: stereo - selective synthesis and biological activity. Angew. Chem., Int. Ed. 2005, 44, 7024-7028.
27. (c) Chen, K. X.; Njoroge, F. G.; Arasappan, A.; Venkatraman, S.; Vibulbhan, B.; Yang, W.; Parekh, T. N.; Pichardo, J.; Prongay, A.; Cheng, K.-C.; Butkiewicz, N.; Yao, N.; Madison, V.; Girijavallabhan, V. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J. Med. Chem. 2006,49, 995-1005.
28. (d) Arasappan, A.; Njoroge, F. G.; Chen, K. X.; Venkatraman, S.; Parekh, T. N.; Gu, H.; Pichardo, J.; Butkiewicz, N.; Prongay, A.; Madison, V.; Girijavallabhan, V. P2-P4 macrocyclic inhibitors of hepatitis C virus NS3-4A serine protease. Bioorg. Med. Chem. Lett. 2006, 16, 3960-3965.
29. Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y. - T.; Lovey, R. G.; Venkatraman, S.; Pan, W.; Parekh, T.; Pike, R. E.; Ruan, S.; Liu, R.; Baroudy, B.; Agrawal, S.; Chase, R.; Ingravallo, P.; Pichardo, J.; Prongay, A.; Brisson, J.-M.; Hsieh, T. Y.; Cheng, K.-C.; Kemp, S. J.; Levy, O. E.; Lim-Wilby, M.; Tamura, S. Y.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Discovery of SCH 446211 (SCH 6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J. Med. Chem. 2006, 49, 2750-2757.
30. (a) Venkatraman, S.; Wu, W.; Prongay, A.; Girijavallabhan, V.; Njoroge, F. G. Potent inhibitors of HCV-NS3 protease derived from boronic acids. Bioorg. Med. Chem. Lett. 2008, doi: 10.1016/j.bmcl. 2008.10.124.
31. (b) Bennett, J. M.; Campbell, A. D.; Campbell, A. J.; Carr, M. G.; Dunsdon, R. M.; Greening, J. R.; Hurst, D. N.; Jennings, N. S.; Jones, P. S.; Jordan, S.; Kay, P. B.; O'Brien, M. A.; King - Underwood, J.; Raynham, T. M.; Wilkinson, C. S.; Wilkinson, T. C. I.; Wilson, F. X. The identification of α-ketoamides as potent inhibitors ofhepatitis C virus NS3-4A proteinase. Bioorg. Med. Chem. Lett. 2001, 11, 355-357.
32. (c) Han, W.; Hu, Z.; Jiang, X.; Decicco, C. P. α-Ketoamides, α-ketoesters and a-diketones as HCV NS3 protease inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 711-713.
33. Zhang, R.; Beyer, B. M.; Durkin, J.; Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 1999, 270, 268-275.
34. Lohmann, V.; Korner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113.
35. Velazquez, F.; Venkatraman, S.; Wu, W.; Blackman, M.; Prongay, A.; Girijavallabhan, V.; Shih, N.-Y.; Njoroge, F. G. Application of ring-closing metathesis for the synthesis of macrocyclic peptido - mimetics as inhibitors of HCV NS3 protease. Org. Lett. 2007, 9, 3061-3064.
36. Arasappan, A.; Venkatraman, S.; Padilla, A. I.; Wu, W.; Meng, T.; Jin, Y.; Wong, J.; Prongay, A.; Girijavallabhan, V.; Njoroge, F. G. Practical and efficient method for amino acid derivatives containing β-quaternary center: application toward synthesis of hepatitis C virus NS3 serine protease inhibitors. Tetrahedron Lett. 2007, 48, 6343-6347.